Published in J Virol on January 20, 2010
Molecular biology of hepatitis B virus infection. Virology (2015) 1.47
The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol (2014) 1.05
Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation. Front Immunol (2014) 0.88
New insights into the evolutionary rate of hepatitis B virus at different biological scales. J Virol (2015) 0.85
Number of mutations within CTL-defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression. J Med Virol (2011) 0.85
Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution. PLoS One (2014) 0.84
Clinical relevance of hepatitis B virus variants. World J Hepatol (2015) 0.83
BAsE-Seq: a method for obtaining long viral haplotypes from short sequence reads. Genome Biol (2014) 0.82
Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection. J Clin Microbiol (2015) 0.79
A rare HBV subgenotype D4 with unique genomic signatures identified in north-eastern India--an emerging clinical challenge? PLoS One (2014) 0.78
Phylogeography and evolutionary history of hepatitis B virus genotype F in Brazil. Virol J (2013) 0.76
HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses (2017) 0.75
Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients. PLoS One (2016) 0.75
De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline. BMC Bioinformatics (2017) 0.75
Short-Sighted Virus Evolution and a Germline Hypothesis for Chronic Viral Infections. Trends Microbiol (2017) 0.75
To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy. World J Hepatol (2014) 0.75
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol (2017) 0.75
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol (2007) 74.13
PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol (2007) 45.68
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Estimating mutation parameters, population history and genealogy simultaneously from temporally spaced sequence data. Genetics (2002) 10.63
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Accuracy and power of statistical methods for detecting adaptive evolution in protein coding sequences and for identifying positively selected sites. Genetics (2004) 4.22
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Gene flow and genetic drift in a species subject to frequent local extinctions. Theor Popul Biol (1977) 3.98
Libsequence: a C++ class library for evolutionary genetic analysis. Bioinformatics (2003) 3.97
The enigmatic X gene of hepatitis B virus. J Virol (2004) 2.98
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol (2005) 2.52
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 2.28
From hepatitis to hepatoma: lessons from type B viral hepatitis. Science (1993) 2.15
A large variation in the rates of synonymous substitution for RNA viruses and its relationship to a diversity of viral infection and transmission modes. Mol Biol Evol (2004) 2.07
Evolutionary history and phylogeography of human viruses. Annu Rev Microbiol (2008) 1.95
High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology (2006) 1.87
Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology (1999) 1.86
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol (1999) 1.85
Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut (2007) 1.76
Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol (2002) 1.75
Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis (2003) 1.63
A revised evolutionary history of hepatitis B virus (HBV). J Mol Evol (2002) 1.57
Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology (2007) 1.50
Distribution patterns of hepatitis B surface antigen (HBsAg) in the liver of hepatitis patients. J Clin Pathol (1976) 1.41
Molecular evolution of hepatitis B virus over 25 years. J Virol (2006) 1.39
Metapopulation models for historical inference. Mol Ecol (2004) 1.27
Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol (2006) 1.27
A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther (2008) 1.25
Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J Mol Evol (2007) 1.25
Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol (1996) 1.21
Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol (1993) 1.15
Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest (1995) 1.12
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A (2006) 1.11
Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol Lett (2002) 1.09
Estimating mutation rate and generation time from longitudinal samples of DNA sequences. Mol Biol Evol (2001) 1.08
Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology (1988) 1.02
Pathology of chronic hepatitis B virus infection in children: with special reference to the intrahepatic expression of hepatitis B virus antigens. Hepatology (1988) 0.94
Evolution of hepatitis B virus during primary infection in humans: transient generation of cytotoxic T-cell mutants. Gastroenterology (2004) 0.89
The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations? Gastroenterology (2007) 0.87
Rich dynamics of a hepatitis B viral infection model with logistic hepatocyte growth. J Math Biol (2009) 0.84
Studies on the age dependent changes in serum adenosine deaminase activity and its changes in hepatitis. Indian J Clin Biochem (2006) 0.77
Immunohistochemical patterns of hepatitis B surface antigen (HBsAg) in patients with hepatitis, renal homografts recipients and normal carriers. Virchows Arch A Pathol Anat Histol (1977) 0.77
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Global control of hepatitis B virus infection. Lancet Infect Dis (2002) 3.74
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis (2008) 3.01
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology (2004) 2.74
Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol (2005) 2.58
Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol (2013) 2.58
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology (2008) 2.55
How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol (2007) 2.48
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
Universal screening for biliary atresia using an infant stool color card in Taiwan. Hepatology (2008) 2.32
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis (2012) 2.17
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (2003) 2.15
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology (2010) 2.10
Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology (2011) 2.07
Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy. Antivir Ther (2014) 1.99
An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2006) 1.99
Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol (2012) 1.98
High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology (2006) 1.87
Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics (2009) 1.85
RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology (2005) 1.85
Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis (2006) 1.84
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol (2009) 1.82
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol (2002) 1.80
Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology (2010) 1.78
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther (2011) 1.77
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol (2002) 1.76
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology (2007) 1.75
Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol (2007) 1.71
Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology (2007) 1.70
Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology (2010) 1.68
Implication of early-onset biliary atresia and extrahepatic congenital anomalies. Pediatr Int (2010) 1.67
Estrogen receptor α represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4α. Gastroenterology (2012) 1.66
Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution. Proc Natl Acad Sci U S A (2004) 1.66
Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology (2007) 1.63
A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr (2010) 1.60
MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology (2008) 1.60
Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol (2004) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
Tumour necrosis factor-α promoter region polymorphisms affect the course of spontaneous HBsAg clearance. Liver Int (2010) 1.56
Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerg Infect Dis (2003) 1.55
Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol (2004) 1.55
Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. J Gastroenterol (2002) 1.54
Esophageal varices: noninvasive diagnosis with duplex Doppler US in patients with compensated cirrhosis. Radiology (2008) 1.54
Longitudinal study on mutation profiles of core promoter and precore regions of the hepatitis B virus genome in children. Pediatr Res (2004) 1.51
Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun (2004) 1.50
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res (2010) 1.50
Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. J Gastroenterol Hepatol (2006) 1.50
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut (2013) 1.49
Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis (2011) 1.49